Profile data is unavailable for this security.
About the company
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
- Revenue in DKK (TTM)6.08bn
- Net income in DKK1.10bn
- Incorporated1961
- Employees2.76k
- LocationALK-Abello A/SBoege Alle 6-8HOERSHOLM 2970DenmarkDNK
- Phone+45 45747576
- Fax+45 45748690
- Websitehttps://www.alk.net/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Ltd | 11.42bn | 738.51m | 38.31bn | 13.48k | 51.90 | -- | 34.20 | 3.36 | 37.72 | 37.72 | 583.32 | -- | -- | -- | -- | 12,219,440.00 | -- | 1.33 | -- | 1.92 | 71.68 | 60.15 | 6.47 | 1.82 | -- | 16.41 | -- | 39.62 | 12.77 | 4.60 | 155.14 | 6.18 | -4.24 | 0.00 |
| Sumitomo Pharma Co Ltd | 18.45bn | 4.48bn | 38.38bn | 3.83k | 8.55 | 3.26 | 7.16 | 2.08 | 277.11 | 277.11 | 1,141.22 | 727.28 | 0.5438 | 1.95 | 3.99 | 118,318,100.00 | 13.20 | -5.49 | 23.02 | -8.49 | 59.24 | 67.88 | 24.28 | -13.24 | 1.01 | 4.17 | 0.4726 | -- | 26.79 | -3.75 | 107.50 | -10.32 | -0.4856 | -- |
| Beijing Tong Ren Tang Co Ltd | 16.44bn | 1.23bn | 38.74bn | 17.88k | 31.48 | 3.12 | -- | 2.36 | 0.9871 | 0.9871 | 13.19 | 9.96 | 0.5736 | 0.9376 | 11.40 | 1,011,323.00 | 5.99 | 8.13 | 11.72 | 15.95 | 43.19 | 46.02 | 10.45 | 13.34 | 1.89 | -- | 0.1629 | 33.28 | 4.12 | 6.97 | -8.54 | 9.14 | 2.30 | 5.64 |
| Abbott India Ltd | 4.66bn | 1.05bn | 40.22bn | 3.66k | 38.44 | 14.46 | 36.64 | 8.64 | 710.12 | 710.12 | 3,159.83 | 1,887.49 | 1.25 | 4.33 | 14.89 | 18,350,290.00 | 28.05 | 22.42 | 37.91 | 30.42 | 45.97 | 44.59 | 22.47 | 18.83 | 2.09 | 88.92 | 0.0435 | 73.99 | 9.58 | 9.38 | 17.75 | 18.99 | 27.31 | 34.73 |
| Dottikon ES Holding AG | 3.47bn | 989.24m | 41.78bn | 841.00 | 41.70 | 4.85 | 35.00 | 12.04 | 8.75 | 8.75 | 30.70 | 75.26 | 0.3175 | 0.6591 | 6.12 | 535,050.40 | 9.05 | 8.05 | 10.52 | 9.25 | 67.57 | 72.37 | 28.51 | 25.67 | 1.71 | -- | 0.1111 | -- | 18.07 | 17.13 | 30.95 | 26.06 | 23.40 | -- |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 17.81bn | 4.49bn | 43.08bn | 11.76k | 9.43 | 1.57 | 7.87 | 2.42 | 1,241.24 | 1,241.24 | 4,922.29 | 7,429.22 | 0.5762 | 1.33 | 3.69 | 76,662,670.00 | 14.52 | 13.55 | 16.23 | 15.35 | 68.65 | 60.79 | 25.20 | 22.34 | 2.83 | -- | 0.0159 | 40.47 | 6.51 | 11.05 | 50.61 | 38.39 | 8.62 | 51.82 |
| Rhythm Pharmaceuticals Inc | 1.10bn | -1.24bn | 43.12bn | 283.00 | -- | 46.10 | -- | 39.38 | -3.10 | -3.10 | 2.74 | 4.43 | 0.4006 | 1.03 | 6.66 | 616,021.20 | -44.19 | -52.46 | -57.53 | -61.22 | 89.40 | -- | -110.32 | -354.18 | 4.53 | -27.83 | 0.2693 | -- | 68.06 | -- | -43.26 | -- | -- | -- |
| ALK-Abello A/S | 6.08bn | 1.10bn | 44.16bn | 2.76k | 43.81 | 7.82 | 31.32 | 7.27 | 4.98 | 4.98 | 27.51 | 27.86 | 0.7781 | 1.24 | 6.36 | 2,207,773.00 | 14.09 | 6.01 | 16.80 | 7.60 | 65.94 | 61.95 | 18.11 | 8.44 | 1.35 | 46.81 | 0.0699 | 0.00 | 14.78 | 11.08 | 67.70 | -- | 50.82 | -- |
| Aurobindo Pharma Ltd | 23.01bn | 2.42bn | 45.27bn | 9.11k | 18.72 | -- | 12.49 | 1.97 | 60.04 | 60.04 | 571.33 | -- | -- | -- | -- | 36,435,560.00 | -- | 8.62 | -- | 12.13 | 59.35 | 53.55 | 10.50 | 12.38 | -- | 14.24 | -- | 7.25 | 9.39 | 6.55 | 9.86 | 4.15 | 11.98 | -- |
| Beijing Wantai Biolog Pha Ent Co Ltd | 1.63bn | -303.41m | 47.69bn | 3.79k | -- | 4.34 | -- | 29.22 | -0.2438 | -0.2438 | 1.38 | 9.56 | 0.1234 | 1.11 | 0.8599 | 473,789.40 | -2.30 | 17.63 | -2.69 | 22.63 | 48.33 | 83.87 | -18.67 | 33.20 | 3.82 | -- | 0.0295 | 9.99 | -59.25 | 13.66 | -91.49 | -12.65 | 40.51 | -- |
| Alkem Laboratories Ltd | 9.63bn | 1.64bn | 48.18bn | 18.64k | 29.43 | 5.21 | 24.91 | 5.00 | 197.47 | 197.47 | 1,161.71 | 1,116.21 | 0.7427 | 1.71 | 4.97 | 7,451,003.00 | 12.89 | 12.12 | 17.55 | 17.53 | 63.60 | 60.06 | 17.35 | 14.69 | 1.87 | 18.59 | 0.1457 | 28.96 | 2.34 | 9.21 | 20.59 | 13.95 | 13.22 | 12.47 |
| Krystal Biotech Inc | 2.34bn | 1.25bn | 49.31bn | 275.00 | 40.62 | 6.90 | 38.39 | 21.04 | 6.66 | 6.66 | 12.50 | 39.26 | 0.3358 | 0.7616 | 3.29 | 1,356,960.00 | 17.90 | -4.81 | 19.49 | -5.07 | 94.26 | -- | 53.30 | -41.51 | 9.73 | -- | 0.00 | -- | 473.02 | -- | 715.58 | -- | -7.91 | -- |
| 3SBio Inc | 8.23bn | 2.14bn | 49.96bn | 6.27k | 22.71 | 3.14 | 18.73 | 6.07 | 1.08 | 1.08 | 4.14 | 7.81 | 0.3799 | 1.54 | 6.97 | 1,836,852.00 | 10.46 | 7.95 | 15.09 | 10.32 | 85.37 | 83.73 | 27.54 | 22.68 | 2.12 | -- | 0.0899 | -- | 16.53 | 11.36 | 34.93 | 16.51 | 14.65 | -- |
Data as of Feb 11 2026. Currency figures normalised to ALK-Abello A/S's reporting currency: Danish Krone DKK
17.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ATP Arbejdsmarkedets Till�gspensionas of 19 Dec 2025 | 10.11m | 4.99% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 5.12m | 2.53% |
| M&G Investment Management Ltd.as of 28 Nov 2025 | 3.60m | 1.78% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 2.94m | 1.45% |
| Financi�re de l'�chiquier SAas of 31 Dec 2025 | 2.56m | 1.27% |
| Danske Bank A/S (Investment Management)as of 31 Jan 2026 | 2.18m | 1.07% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 2.11m | 1.04% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 2.07m | 1.02% |
| BI Asset Management Fondsm�glerselskab A/Sas of 30 Jan 2026 | 1.97m | 0.97% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 1.88m | 0.93% |
More ▼
Data from 30 Jun 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
